Catheter Precision reports FY2023 revenue $442K; net loss ($70.6M) includes $60.9M goodwill impairment

Catheter Precision, Inc.

Full-year 2023 revenue $442K vs $14K in 2022; Q4 revenue $128.8K vs zero in prior-year quarter.
Net loss of ($70.6M) includes $60.9M one-time goodwill impairment; operating expenses $78.5M.
Cash on hand $3.6M as of Dec 31, 2023; cash decreased $12.3M during the year.
Clinical progress: VIVO European Registry enrolled 125 patients; LockeT initial trial >100 patients, second trial expected mid-2024.
Intellectual property: 8 patent applications filed and 6 patents issued in 2023.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Catheter Precision, Inc. reported the quarter and year ended December 31, 2023 results: revenue $442 thousand, net income ($70.6) million.

Period: the quarter and year ended December 31, 2023
Revenue: $442 thousand
Net income: ($70.6) million
Result: reported results

Exact text from the filing

Total revenues for the year ended December 31, 2023 were $442 thousand.

View on SEC.gov

321 earnings releases filed in the last 30 days. Browse all earnings releases →

Catheter Precision, Inc. filing history →

Source: SEC EDGAR

accession 0001654954-24-004178

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.